Why do young women smoke VI. A controlled study of nicotine effects on attention: Pharmacogenetic interactions

Pharmacogenomics Journal

Volumn 11, Issue 1, 2011, Pages 45-52

  Rigbi, A ^a   Yakir, A ^a   Sarner Kanyas, K ^a   Pollak, Y ^b   Lerer, B ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

attention; nicotine; nicotinic acetylcholine receptor genes; response inhibition; smoking; women

Indexed keywords

CAFFEINE; NICOTINE; PLACEBO;

ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CHRNA7 GENE; CIGARETTE SMOKING; CLINICAL ARTICLE; CONTINUOUS PERFORMANCE TASK; CONTROLLED STUDY; EXPERIMENTAL TEST; FEMALE; GENE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HETEROZYGOTE; HUMAN; MATCHING FAMILIAR FIGURES TEST; MENTAL TASK; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING CESSATION; SUBSTANCE ABUSE; SYMPTOMATOLOGY; TASK PERFORMANCE; TOBACCO DEPENDENCE; TOWER OF LONDON TEST; TYPES OF STUDY;

ADULT; ATTENTION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BEHAVIOR; CASE-CONTROL STUDIES; COGNITION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; NEUROPSYCHOLOGICAL TESTS; NICOTINE; PSYCHOMOTOR PERFORMANCE; RECEPTORS, NICOTINIC; SMOKING; TASK PERFORMANCE AND ANALYSIS; TOBACCO USE DISORDER; WOMEN'S HEALTH;

EID: 79151477536     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2010.15     Document Type: Article

References (46)

1. Anderson P. Global use of alcohol, drugs and tobacco. Drug Alcohol Rev 2006; 25: 489-502.
2. World Health Organization. Report on the Global Tobacco Epidemic, 2008 - the Mpower Package. World Health Organization: Geneva, Switzerland. (Available from: http://apps.who.int/bookorders/anglais/detart1.jsp?sesslan=1&codlan= 1&codcol=93&codcch=220).
3. Israel Ministry of Health. Minister of Health Report About Smoking in Israel. Israel Ministry of Health: Jerusalem, Israel, 2007-2008. (Available from: http://www.health.gov.il/download/pages/smoke18052009.pdf (Hebrew)).
4. US Centers for Disease Control and Prevention. Global Youth Tobacco Survey. US Centers for Disease Control and Prevention (CDC): Atlanta, GA, 2007. (Available from: http://www.cdc.gov/Tobacco/global/gyts/).
5. Payne S. Gender in Lung Cancer and Smoking Research. World Health Organization, Department of Gender, Women, Health Family and Community Health, 2005. (Available from: http://www.who.int/ gender/documents/LungCancerlast2.pdf) .
6. Israel Ministry of Health. Minister of Health Report About Smoking in Israel. Israel Ministry of Health: Jerusalem, Israel, 2004-2005. (Available from: http://www.health.gov.il/download/forms/a2752-ALL-310705.pdf (Hebrew)).
7. Israel Ministry of Health. Minister of Health Report About Smoking in Israel. Israel Ministry of Health: Jerusalem, Israel, 2002-2003. (Available from: http://www.health.gov.il/Download/pages/isun2003. pdf (Hebrew)).
8. Greenbaum L, Kanyas K, Karni O, Merbl Y, Olender T, Horowitz A et al. Why do young women smoke? I. Direct and interactive effects of environment, psychological characteristics and nicotinic cholinergic receptor genes. Mol Psychiatry 2006; 11: 312-322.
9. Lerer E, Kanyas K, Karni O, Ebstein R, Lerer B. Why do young women moke? II. Role of traumatic life experience, psychological characteristics and serotonergic genes. Mol Psychiatry 2006; 11: 771-781.
10. Yakir A, Rigbi A, Kanyas K, Pollak Y, Kahana G, Karni O et al. Why do young women smoke? III. Attention and impulsivity as neurocognitive predisposing factors. Eur Neuropsychopharmacol 2007; 17: 339-351.
11. Segman R, Kanyas K, Karni O, Lerer E, Goltser-Dubner T, Pavlov V et al. Why do young women smoke? IV. Role of genetic variation in the dopamine transporter and lifetime traumatic experience. Am J Med Genet B 2007; 144B: 533-540.
12. Rigbi A, Kanyas K, Yakir A, Greenbaum L, Pollak Y, Ben-Asher E et al. Why do young women smoke? V. Role of direct and interactive effects of nicotinic cholinergic receptor gene variation on neurocognitive function. Genes Brain Behav 2008; 7: 164-172.
13. Heishman SJ, Taylor RC, Hennigfield JE. Nicotine and smoking: a review of effects on human performance. Exp Clin Psychopharmacol 1994; 2: 345-395.
14. Heishman SJ. What aspects of human performance are truly enhanced by nicotine. Addiction 1998; 93: 317-320.
15. Levin DL, McClernon FG, Rezvani AH. Nicotine effects on cognitive function: behavioral characterization, pharmacological specification and anatomic localization. Psychopharmacology 2006; 184: 523-539.
16. Newhouse PA, Potter A, Singh A. Effects of nicotine stimulation on cognitive performance. Curr Opin Pharmacol 2004; 4: 36-46.
17. Sherwood N. Effects of nicotine on human psychomotor performance. Hum Psychopharmacol 1993; 8: 155-184.
18. Cincotta SL, Yorek MS, Moschak TM, Lewis SR, Rodefer JS. Selective nicotinic acetylcholine receptor agonists: potential therapies for neuropsychiatric disorders with cognitive dysfunction. Curr Opin Investig Drugs 2008; 9: 47-56.
19. Forgacs PB, Bodis-Wollner I. Nicotinic receptors and cognition in Parkinson's disease: the importance of neuronal synchrony. J Neural Transm 2004; 111: 1317-1331.
20. Ochoa EL, Lasalde-Dominicci J. Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking. Cell Mol Neurobiol 2007; 27: 609-639.
21. Sacco KA, Bannon KL, George TP. Nicotine receptor mechanisms and cognition in normal states and neuropsychiatric disorders. J Psychopharmacol 2004; 18: 457-474.
22. Wilens TE, Decker MW. Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition. Biochem Pharmacol 2007; 74: 1212-1223.
23. Kumari V, Postma P. Nicotine use in schizophrenia: the self medication hypotheses. Neurosci Biobehav Rev 2005; 29: 1021-1034.
24. Potter AS, Newhouse PA, Bucci DJ. Central nicotinic cholinergic systems: a role in the cognitive dysfunction in attention-deficit/ hyperactivity disorder? Behav Brain Res 2006 15; 175: 201-211.
25. Mansvelder HD, van Aerde KI, Couey JJ, Brussaard AB. Nicotinic modulation of neuronal networks: from receptors to cognition. Psychopharmacology 2006; 184: 292-305.
26. Portugal GS, Gould TJ. Genetic variability in nicotinic acetylcholine receptors and nicotine addiction: converging evidence from human and animal research. Behav Brain Res 2008; 193: 1-16.
27. Espeseth T, Endestad T, Rootwelt H, Reinvang I. Nicotine receptor gene CHRNA4 modulates early event-related potentials in auditory and visual oddball target detection tasks. Neuroscience 2007; 147: 974-985.
28. Espeseth T, Greenwood PM, Reinvang I, Fjell AM, Walhovd KB, Westlye LT et al. Interactive effects of APOE and CHRNA4 on attention and white matter volume in healthy middle-aged and older adults. Cogn Affect Behav Neurosci 2006; 6: 31-43.
29. Greenwood PM, Fossella JA, Parasuraman R. Specificity of the effect of a nicotinic receptor polymorphism on individual differences in visuospatial attention. J Cogn Neurosci 2005; 17: 1611-1620.
30. Parasuraman R, Greenwood PM, Kumar R, Fossella J. Beyond heritability: neurotransmitter genes differentially modulate visuospatial attention and working memory. Psychol Sci 2005; 16: 200-207.
31. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict 1991; 86: 1119-1127.
32. Kertzman S, Ben-Nahum Z, Sirota A. CogScan V4.0-Cognitive Scanning System. System Description. AnimaScan Ltd: Ashdod, Israel, 2003.
33. Brown TE. Brown Attention-Deficit Disorder Scales Manual. The Psychological Corporation: San Antonio, TX, 1996.
34. Murphy KR, Adler LA. Assessing attention-deficit/hyperactivity disorder in adults: focus on rating scales. J Clin Psychiatry 2004; 65(Suppl 3): 12-17.
35. Barratt E. Barratt impulsiveness scale, version 11 (BSI-11). J Clin Psychol 1995; 51: 768-774.
36. Benowitz NL. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin Pharmacol Ther 2008; 83: 531-541.
37. Hukkanen J, Peyton III J, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev 2005; 57: 79-155.
38. Russel MAH. Nicotine intake by smokers: are rates of absorption or steady state levels more important?. In: Rand MJ, Thurau K (eds). The Pharmacology of Nicotine. IRL press: Oxford, UK, 1987, pp 375-402.
39. Kline P. An Easy Guide to Factor Analysis. Routledge: New York, NY, 1993.
40. Kollins SH, McClernon FJ, Fuemmeler BF. Association between smoking and attention-deficit/hyperactivity disorder symptoms in a population-based sample of young adults. Arch Gen Psychiatry 2005; 62: 1142-1147.
41. Pomerleau OF, Downey KK, Stelson FW, Pomerleau CS. Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder. J Subst Abuse 1995; 7: 373-378.
42. McClernon FJ, Kollins SH. ADHD and smoking: from genes to brain to behavior. Ann N Y Acad Sci 2008; 1141: 131-147.
43. Cauli O, Morelli M. Caffeine and the dopaminergic system. Behav Pharmacol 2005; 16: 63-77.
44. Swanson JA, Lee JW, Hopp JW. Caffeine and nicotine: a review of their joint use and possible interactive effects in tobacco withdrawal. Addict Behav 1994; 19: 229-256.
45. Riccio CA, Waldrop JJ, Reynolds CR, Lowe P. Effects of stimulants on the continuous performance test (CPT): implications for CPT use and interpretation. J Neuropsychiatry Clin Neurosci 2001; 13: 326-335.
46. Tucha O, Lange KW. Effects of nicotine chewing gum on a real-life motor task: a kinematic analysis of handwriting movements in smokers and non-smokers. Psychopharmacology (Berl) 2004; 173: 49-56.